Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTX660 +/- ASTX727 in R/R AML
NCT04155580Phase 1Terminated
- Sponsor
- Astex Pharmaceuticals
- Start
- Jun 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tolinapant in acute myeloid leukemia (AML) (4 arms), sponsored by Astex Pharmaceuticals. Primary endpoint: Treatment-Emergent Adverse Events at 30 months. Started Jun 2020; status: terminated.
02
Drugs
tolinapant
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04155580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04155580.